Bicalutamide-induced interstitial lung disease

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Androgen deprivation therapy, which is the standard treatment for metastatic prostate cancer, includes nonsteroidal antiandrogenic drugs, such as flutamide, nilutamide and bicalutamide. Of them, bicalutamide rarely induces interstitial pneumonia. We report a case of bicalutamide-induced interstitial pneumonia. A 68-year old male diagnosed with prostate cancer and multiple bone metastases presented with dry cough and low grade fever for 3 days. He had taken bicalutamide (50 mg/day) for 13 months. High resolution computed tomography revealed ground glass opacity in his right upper lung. The laboratory studies showed no eosinophilia in the serum and bronchoalveolar lavage fluid. Despite the use of antimicrobial agents for 2 weeks, the extent of the lung lesions increased to the left upper and right lower lung. He had no environmental exposure, collagen vascular disease and microbiological causes. Under the suspicion of bicalutamide-induced interstitial pneumonia, bicalutamide was stopped and prednisolone (1 mg/kg/ day) was initiated. The symptoms and radiologic abnormalities were resolved with residual minimal fibrosis. Copyright©2010. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Cite

CITATION STYLE

APA

Kim, Y. K., Kim, Y. H., Lee, J. J., Choi, C. W., Yoo, J. H., Park, M. J., & Kang, H. M. (2010). Bicalutamide-induced interstitial lung disease. Tuberculosis and Respiratory Diseases, 68(4), 226–230. https://doi.org/10.4046/trd.2010.68.4.226

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free